



Learn & Improve Professional Skills (LIPS) Track – Session 10

Neuroimaging Committee

Tuesday, September 12, 09:45 – 11:15

Session Title

The Sunrise of Alpha-Synuclein in vivo Brain Imaging

Chairpersons

Henryk Barthel (Leipzig, Germany)

Donatienne Van Weehaeghe (Gent, Belgium)

Programme

09:45 – 10:15 **Ruben Smith** (Lund, Sweden): The Need of an Alpha-Synuclein Biomarker

10:15 – 10:35 **Donatienne Van Weehaeghe** (Gent, Belgium): Alpha-Synuclein in Parkinson's Disease

10:35 – 10:55 **Nelleke Tolboom** (Utrecht, Netherlands): Alpha-Synuclein in Lewy Body Dementia

10:55 – 11:15 **Henryk Barthel** (Leipzig, Germany): Alpha-Synuclein in Multi System Atrophy

Educational Objectives

1. Broadening knowledge on the role of alpha-synuclein in different neurodegenerative disorders
2. Discussing the clinical and research needs of an alpha-synuclein biomarker
3. Providing an overview on the currently tested alpha-synuclein tracers

Summary

Several neurodegenerative disorders, like Parkinson's disease, Lewy body dementia and multi system atrophy are histopathologically characterized by alpha-synuclein aggregates in different brain areas. No technique is so far available to visualize these aggregates in vivo. There are, however, increasing efforts by academic and commercial groups to develop suitable alpha-synuclein PET tracers.

Key Words

Alpha-Synuclein, PET, Parkinson, DLB, MSA